Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

AVATAR Trial

ABSTRACT: A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: the AVATAR Trial

INSTRUMENT(S): Illumina NovaSeq 6000

ORGANISM(S): Homo Sapiens

SUBMITTER: La Paz University Hospital and Fuenlabrada Hospital

PROVIDER: PRJEB81716 | EVA | 2024-10-28

REPOSITORIES: EVA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	AVA148_biopsy.vcf.csi	Other
	AVA148_biopsy.vcf.gz	Vcf
	AVA148_biopsy.vcf.gz.csi	Vcf
	AVA148_blood.vcf.csi	Other
	AVA148_blood.vcf.gz	Vcf

Items per page:

1 - 5 of 552

Similar Datasets

Consensus molecular subtypes as biomarkers of FU/FA maintenance therapy with or without panitumumab in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212).

Project description:Customized Nanostring PanCancer Progression Panel performed on FFPE tumor tissue derived from treatment naive metastatic colorectal cancer patients included into the randomized phase 2 PanaMa trial.

2023-02-15 | GSE221953 | GEO

Ex vivo effects of Tenofovir on four vaginal epithelial cell lines

2015-02-23 | GSE57026 | GEO

Systems Biology Analysis of Tenofovir 1% Gel in a Phase I Rectal Microbicide Trial

2015-02-23 | GSE57025 | GEO

An integrated functional and clinical genomics approach reveal genes driving aggressive metastatic prostate cancer [ATAC-Seq]

Project description:Genomic sequencing of many thousands of tumors has revealed many genes associated with specific types of cancer. Similarly, large scale CRISPR functional genomics efforts have mapped genes required for proliferation or survival in hundreds of cancer cell lines. Despite this, for specific disease subtypes, such as metastatic prostate cancer, it is likely that there exist many undiscovered tumor specific genetic dependencies, such as prostate cancer specific drivers, that represent drug targets. To identify such genetic dependencies, we performed genome-scale CRISPRi screens in metastatic prostate cancer models. We then created a pipeline in which we integrated publicly available pan-cancer functional genomics data with our metastatic prostate cancer functional and clinical genomics data to identify genes that can drive aggressive prostate cancer phenotypes. Our integrative analysis of these data revealed two known prostate cancer specific driver genes, AR and HOXB13, as the top two hits and also nominated a number of unexpected genes. In this study we highlight the strength of an integrated clinical and functional genomics pipeline and focus on two hit genes, KIF4A and WDR62. We demonstrate that both KIF4A and WDR62 drive aggressive prostate cancer phenotypes in vitro and in vivo in multiple models, irrespective of AR-status, and are also associated with poor patient outcome.

2021-06-17 | GSE178329 | GEO

An integrated functional and clinical genomics approach reveal genes driving aggressive metastatic prostate cancer [RNA-Seq]

2021-06-17 | GSE178300 | GEO

SNP array data from the Cancer Cell Line Encyclopedia (CCLE)

Project description:The Cancer Cell Line Encyclopedia (CCLE) project is a collaboration between the Broad Institute, the Novartis Institutes for Biomedical Research and the Genomics Novartis Foundation to conduct a detailed genetic and pharmacologic characterization of a large panel of human cancer models It consists of a compilation of gene expression, chromosomal copy number, and massively parallel sequencing data from nearly 1,000 human cancer cell lines. All raw and processed data are available through an integrated portal on www.broadinstitute.org/ccle

2012-03-20 | GSE36138 | GEO

Systems Biology Analysis of Tenofovir 1% Gel in a Phase I Rectal Microbicide Trial

Project description:In MTN-007, a phase 1, randomized, double-blinded rectal microbicide trial, we used systems genomics/proteomics to determine the effect of tenofovir 1% gel, nonoxynol-9 2% gel, placebo gel or no treatment on rectal biopsies taken at baseline, after one application or after seven daily applications (15 subjects/arm). Experiments were repeated using primary vaginal epithelial cells from four healthy women. 192 Arrays (8 donors per treatment group, 2 biopsy sites per donor (9cm and 15 cm), biopsies taken at baseline, after a single application, and after 7 daily applications)

2015-02-23 | E-GEOD-57025 | biostudies-arrayexpress

Ex vivo effects of Tenofovir on four vaginal epithelial cell lines

Project description:In MTN-007, a phase 1, randomized, double-blinded rectal microbicide trial, we used systems genomics/proteomics to determine the effect of tenofovir 1% gel, nonoxynol-9 2% gel, placebo gel or no treatment on rectal biopsies taken at baseline, after one application or after seven daily applications (15 subjects/arm). Experiments were repeated using primary vaginal epithelial cells from four healthy women. 36 Arrays (3 primary vaginal epithelial cell lines from healthy women donors, cultured with or without 50uM or 500 uM Tenofovir for 1,4,7, or 14 days per donor cell line. A no treatment, culture media only control was included for each donor cell line and for each time point.

2015-02-23 | E-GEOD-57026 | biostudies-arrayexpress

Expression data from the Cancer Cell Line Encyclopedia (CCLE)

2012-03-20 | E-GEOD-36133 | biostudies-arrayexpress

SNP array data from the Cancer Cell Line Encyclopedia (CCLE)

2012-03-20 | E-GEOD-36138 | biostudies-arrayexpress